ESC 2017: The GLAGOV Trial

Published: 25 Sep 2017

  • Views:

    Views Icon 266
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

This interview with Stephen Nicholls from South Australian Health and Medical Research Institute, Adelaide, AU on the Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis (GLAGOV) at ESC 2017.

Filmed by Radcliffe Cardiology on-site at ESC 2017.